Danaher Co. (NYSE:DHR) Receives $268.27 Average PT from Brokerages

Danaher Co. (NYSE:DHR) has earned an average rating of “Moderate Buy” from the sixteen brokerages that are covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $270.00.

Several brokerages have issued reports on DHR. KeyCorp increased their target price on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Royal Bank of Canada lifted their target price on Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. TD Cowen increased their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday. Citigroup lifted their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Robert W. Baird increased their target price on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday.

Insider Activity at Danaher

In other Danaher news, Director Teri List sold 3,289 shares of the company’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the sale, the director now owns 19,726 shares in the company, valued at approximately $4,898,360.32. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Teri List sold 3,289 shares of the company’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Rainer Blair sold 47,175 shares of the stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the transaction, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 84,132 shares of company stock worth $21,022,795. 11.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Danaher

A number of large investors have recently modified their holdings of the business. Norges Bank acquired a new position in Danaher in the 4th quarter valued at about $1,752,382,000. Wellington Management Group LLP boosted its stake in shares of Danaher by 18.6% in the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock valued at $6,185,203,000 after buying an additional 3,905,449 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in shares of Danaher by 214.4% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock worth $711,051,000 after buying an additional 2,096,038 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Danaher by 10.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after buying an additional 1,619,586 shares during the period. Finally, Capital International Investors raised its holdings in Danaher by 9.1% in the fourth quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after acquiring an additional 1,334,781 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

DHR opened at $245.82 on Tuesday. Danaher has a 12-month low of $182.09 and a 12-month high of $259.00. The business’s fifty day simple moving average is $248.94 and its 200-day simple moving average is $230.88. The company has a market capitalization of $182.04 billion, a price-to-earnings ratio of 41.66, a PEG ratio of 4.24 and a beta of 0.83. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.48%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. During the same quarter in the previous year, the business posted $2.36 EPS. The company’s quarterly revenue was down 2.6% compared to the same quarter last year. On average, equities research analysts anticipate that Danaher will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend is Wednesday, March 27th. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.